EyePoint Pharmaceuticals Q4 2019 Earnings Report
Key Takeaways
EyePoint Pharmaceuticals reported total revenues of $8.6 million for Q4 2019, driven by net product revenues of $7.9 million from DEXYCU and YUTIQ. Customer demand for DEXYCU and YUTIQ increased significantly compared to Q3 2019. The company is advancing EYP-1901 towards clinical development and expects continued customer demand growth in 2020.
Total revenues reached $8.6 million in Q4 2019.
Net product revenues were $7.9 million in Q4 2019, with $4.8 million from YUTIQ and $3.1 million from DEXYCU.
Customer demand for DEXYCU and YUTIQ increased 111% and 59%, respectively, compared to Q3 2019.
EYP-1901 is advancing toward clinical development as a potential treatment for wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.